|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current status of diagnosis and treatment of bladder cancer in China-Analyses of Chinese Bladder Cancer Consortium database显示文摘Objective:To investigate current status of diagnosis and treatment of bladder cancer in China.Methods:A database was generated by Chinese Bladder Cancer Consortium(CBCC).From January 2007 to December 2012,14,260 cases from 44 CBCC centers were included.Data of diagnosis,treatment and pathology were collected.Results:The average age was 63.5 year-old and most patients were male(84.3%).The most common histologic types were urothelial carcinoma(91.4%),adenocarcinoma(1.8%),and squamous carcinoma(1.9%).According to 1973 and 2004 WHO grading system,42.0%,41.0%,and 17.0% of patients were grade 1,2,and 3,and 16.0%,48.7%,and 35.3% of patients were papillary urothelial neoplasms of low malignant potential,low,and high grade,respectively.Non-muscle invasive bladder cancer(NMIBC)and muscle invasive bladder cancer(MIBC)were 25.2% and 74.1%,respectively(0.8% not clear).Carcinoma in situ was only 2.4%.Most patients were diagnosed by white-light cystoscopy with biopsy(74.3%).Fluorescence and narrow band imaging cystoscopy had additional detection rate of 1.0% and 4.0%,respectively.Diagnostic transurethral resection(TUR)provided detection rate of 16.9%.Most NMIBCs were treated with TUR(89.2%).After initial TUR,2.6%accepted second TUR,and 45.7%,69.9%,and 58.7% accepted immediate,induced,and maintenance chemotherapy instillation,respectively.Most MIBCs were treated with radical cystectomy(RC,59.7%).Laparoscopic RCs were 35.1%,while open RC 63.4%.Extended and standard pelvic lymph node dissection were 7% and 66%,respectively.Three most common urinary diversions were orthotopic neobladder(44%),ileal conduit(31%),and ureterocutaneostomy(23%).Only 2.3% of patients accepted neo-adjuvant chemotherapy and only 18%of T3 and T4 patients accepted adjuvant chemotherapy.Conclusion:Disease characteristics are similar to international reports,while differences of diagnosis and treatment exist.This study can provide evidences for revisions of the guideline on bladder cancer in China. | Kaiwen Li Tianxin Lin 无 Wei Xue Xin Mu Enci Xu Xu Yang Fubao Chen Guangyong Li Lulin Ma Guoliang Wang Chaozhao Liang Haoqiang Shi Ming Li Mao Tang Xueyi Xue Yisong Lv Yaoliang Deng Chengyang Li Zhiwen Chen Xiaozhou Zhou Fengshuo Jin Xudong Liu Jinxin Wei Lei Shi Xin Gou Weiyang He Liqun Zhou Lin Cai Baiye Jin Guanghou Fu Xiangbo Kong Hongyan Sun Ye Tian Lang Feng Tiejun Pan Yiyi Wu Dongwen Wang Hailong Hao Benkang Shi Yaofeng Zhu Qiang Wei Ping Han Changli Wu Dawei Tian Zhangqun Ye Zheng Liu Zhiping Wang Junqiang Tian Lin Qi Minfeng Chen Wei Li Jinchun Qi Gongxian Wang Longlong Fu Zhaolin Sun Guangheng Luo Zhoujun Shen Zhaowei Zhu Jinchun Xing Zhun Wu Dong Wei Xin Chen Yanqun Na Hongfeng Guo Chunxi Wang Zhihua Lu Chuize Kong Yang Liu Jin Yang Jianyun Hu Xin Gao Jielin Li Changjun Yin Pu Li Shan Chen Zhen Du Jiongming Li Yongji Yan Xu Zhang Shuang Huang Fangjian Zhou Zhiling Zhang Yinghao Sun Shuxiong Zeng Song Cen Jiaquan Zhou Hanzhong Li Jin Wen Jian Huang | 2015 | Asian Journal of Urology2015，2，2： | 21 |
| 2 | Prostate cancer in Asia:A collaborative report显示文摘The incidence of prostate cancer(PCa)within Asian population used to be much lower than in the Western population;however,in recent years the incidence and mortality rate of PCa in some Asian countries have grown rapidly.This collaborative report summarized the latest epidemiology information,risk factors,and racial differences in PCa diagnosis,current status and new trends in surgery management and novel agents for castration-resistant prostate cancer.We believe such information would be helpful in clinical decision making for urologists and oncologists,health-care ministries and medical researchers. | Rui Chen Shancheng Ren 无 Ming Kwong Yiu Ng Chi Fai Wai Sam Cheng Lap Hong Ian Seiji Naito Tadashi Matsuda Elijah Kehinde Ali Kural Jason Yichun Chiu Rainy Umbas Qiang Wei Xiaolei Shi Liqun Zhou Jian Huang Yiran Huang Liping Xie Lulin Ma Changjun Yin Danfeng Xu Kexin Xu Zhangqun Ye Chunxiao Liu Dingwei Ye Xin Gao Qiang Fu Jianquan Hou Jianlin Yuan Dalin He Tiejun Pan Qiang Ding Fengshuo Jin Benkang Shi Gongxian Wang Xiuheng Liu Dongwen Wang Zhoujun Shen Xiangbo Kong Wanhai Xu Yaoliang Deng Haibo Xia Alexa NCohen Xu Gao Chuanliang Xu Yinghao Sun | 2014 | Asian Journal of Urology2014，1，1： | 13 |
| 3 | Full-scale experiment for segmental linings of deep-buried shield tunnels bearing high inner water pressure:Comparison of mechanical behaviors of continuous-and stagger-jointed structures显示文摘Full-scale loading tests were performed on shield segmental linings bearing a high earth pressure and high inner water pressure,focus-ing on the effects of the inner water load and assembly manner on the mechanical properties of the segmental linings.The test results indicate that the deep-buried segmental linings without inner pressure have a high safety reserve.After the action of high inner water pressure,the lining deformation will increase with the reduction of the safety reserve,caused by the significant decrease in the axial force in the linings.Because the bending moment at the segmental joints is transferred to the segment sections in the adjacent ling rings,the convergence deformation,openings of segmental joints,and bolt strains are smaller for the stagger-jointed lining than those for the continuous-jointed lining;however,dislocations appear in the circumferential joints owing to the stagger-jointed assembly.Although it significantly improves the mechanical performance of the segmental lining,stagger-jointed assembly results in compromising the water-proofing safety of circumferential joints.The stagger-jointed assembly manner can be considered to improve the service performance of shield tunnels bearing high inner water pressure on the premise that circumferential joint waterproofing is satisfied. | Long Zhou Yi Shen Linxing Guan Zhiguo Yan Wei Sun Yaoliang Li | 2023 | Underground Space2023，，1： | 1 |
| 4 | Development of a potent benzonitrile-based inhibitor of glutaminyl-peptide cyclotransferase-like protein(QPCTL)with antitumor efficacy显示文摘Dear Editor,Immune checkpoint therapies manipulating the immune system to eliminate tumor cells have shown remarkable clinical efficacy in treating various cancers.CD47,an emerging efficient immune checkpoint,is crucial for cancer cells to evade macrophagemediated phagocytosis by interaction with signal-regulatory proteinα(SIRPα).Antibodies blocking the CD47/SIRPαinteraction have been effective to promote macrophage-mediated phagocytosis in various types of cancer in mice and humans.CD47 is not only highly expressed in tumor cells,but also normal cells,such as red blood cells(RBCs).Thus,during clinical trials involving cancer patients,anti-CD47 antibodies may promote the macrophagesmediated phagocytosis of RBCs,ultimately inducing undesirable anemia side effects.In contrast,small molecule inhibitors interrupting CD47/SIRPαaxis have shown potential to overcome the anemia,possibly due to their lower immunogenicity and shorter half-life compared to antibodies.1 Hence,developing the novel strategies,especially those without the anemia side effect,to intervene in CD47/SIRPαinteraction will benefit cancer immunotherapy. | Lei Yu Pengcheng Zhao Yaoliang Sun Zening Zheng Wenhao Du Lishan Zhang Yaxu Li Longyan Xie Shilin Xu Ping Wang | 2024 | Signal Transduction and Targeted Therapy2024，9，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员